Moleculin Biotech CS (MBRX) Stock Price, Quote & News

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 300 5160

Website: moleculin.com

Address:

5300 Memorial Drive, Suite 950, Houston, United States

Trader1141 Apr. 9 at 11:47 AM

$BIAF $MBRX $PFSA $SLS $ELAB

0 · Reply

Trader1141 Apr. 9 at 11:01 AM

$UCAR Next week Cancer Summit dont forget to buy some $BIAF $SLS $MBRX $PFSA

0 · Reply

Brokechump Apr. 8 at 2:47 PM

$MBRX will stay upall day to last when some Ahole sells 13 shares

0 · Reply

Brokechump Apr. 7 at 5:17 PM

$MBRX move on up !

0 · Reply

Stormra Apr. 7 at 1:55 PM

$MBRX

0 · Reply

MrTicker Apr. 7 at 12:19 PM

$MBRX BioRestorative Therapies Announces Strategic Collaboration With 203 Creates To Commercialize BioRestorative's Biocosmeceutical Platform BENZINGA 7:18 AM ET 4/7/2026

0 · Reply

MrTicker Apr. 7 at 12:17 PM

$MBRX Partnership to drive brand architecture, go-to-market execution, and global launch of the Company’s product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BRTX) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced a strategic collaboration with 203 Creates, LLC, a Stamford, Connecticut-based firm specializing in the development, marketing, and growth of luxury, premium, and science-backed brands.

0 · Reply

MrTicker Apr. 7 at 12:16 PM

$MBRX BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform GLOBENEWSWIRE 7:15 AM ET 4/7/2026

0 · Reply

123rickiek Apr. 6 at 11:11 PM

$MBRX Come here little mouse i have some cheese on a big trap wanting for you. Its really good cheese and make sure you smile when the trap crushes your head!!! Dude you been spamming here forever give it a break!!! 😂

0 · Reply

cheeseandsmile Apr. 1 at 1:39 PM

$MBRX Eli is in talks with Moleculin about license deal

1 · Reply

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

Mar 23, 2026, 8:31 AM EDT - 22 days ago

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

Mar 19, 2026, 8:36 AM EDT - 26 days ago

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Mar 17, 2026, 9:05 AM EDT - 4 weeks ago

Moleculin to Present at 38th Annual ROTH Conference

Mar 11, 2026, 9:00 AM EDT - 4 weeks ago

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Feb 19, 2026, 8:39 AM EST - 7 weeks ago

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Feb 18, 2026, 8:20 AM EST - 7 weeks ago

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Feb 17, 2026, 8:35 AM EST - 2 months ago

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Feb 13, 2026, 8:32 AM EST - 2 months ago

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Feb 5, 2026, 9:15 AM EST - 2 months ago

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Jan 13, 2026, 8:55 AM EST - 3 months ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Jan 12, 2026, 8:36 AM EST - 3 months ago

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Dec 17, 2025, 8:31 AM EST - 4 months ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Dec 10, 2025, 8:30 AM EST - 4 months ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Dec 9, 2025, 8:07 AM EST - 4 months ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 8, 2025, 8:21 AM EST - 4 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Nov 26, 2025, 9:15 AM EST - 4 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:00 AM EST - 4 months ago

Moleculin Announces Reverse Stock Split

Nov 13, 2025, 8:36 AM EST - 5 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 12, 2025, 8:37 AM EST - 5 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Oct 30, 2025, 8:40 AM EDT - 5 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 29, 2025, 8:35 AM EDT - 5 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 23, 2025, 8:00 AM EDT - 6 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Sep 25, 2025, 8:35 AM EDT - 7 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 9, 2025, 8:45 AM EDT - 7 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 8, 2025, 8:30 AM EDT - 7 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Aug 28, 2025, 8:30 AM EDT - 8 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 27, 2025, 8:45 AM EDT - 8 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Aug 14, 2025, 9:15 AM EDT - 8 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 8:05 AM EDT - 8 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 6, 2025, 8:40 AM EDT - 8 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Jul 30, 2025, 8:35 AM EDT - 9 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 22, 2025, 8:45 AM EDT - 9 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 17, 2025, 8:25 AM EDT - 9 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 9, 2025, 8:35 AM EDT - 9 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jun 20, 2025, 9:20 AM EDT - 10 months ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 10 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 10 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 11 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

May 14, 2025, 7:30 AM EDT - 11 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:40 AM EDT - 1 year ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 7, 2025, 9:00 AM EDT - 1 year ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 6, 2025, 9:00 AM EDT - 1 year ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 5, 2025, 8:45 AM EDT - 1 year ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Apr 29, 2025, 8:35 AM EDT - 1 year ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Trader1141 Apr. 9 at 11:47 AM

$BIAF $MBRX $PFSA $SLS $ELAB

0 · Reply

Trader1141 Apr. 9 at 11:01 AM

$UCAR Next week Cancer Summit dont forget to buy some $BIAF $SLS $MBRX $PFSA

0 · Reply

Brokechump Apr. 8 at 2:47 PM

$MBRX will stay upall day to last when some Ahole sells 13 shares

0 · Reply

Brokechump Apr. 7 at 5:17 PM

$MBRX move on up !

0 · Reply

Stormra Apr. 7 at 1:55 PM

$MBRX

0 · Reply

MrTicker Apr. 7 at 12:19 PM

$MBRX BioRestorative Therapies Announces Strategic Collaboration With 203 Creates To Commercialize BioRestorative's Biocosmeceutical Platform BENZINGA 7:18 AM ET 4/7/2026

0 · Reply

MrTicker Apr. 7 at 12:17 PM

0 · Reply

MrTicker Apr. 7 at 12:16 PM

$MBRX BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform GLOBENEWSWIRE 7:15 AM ET 4/7/2026

0 · Reply

123rickiek Apr. 6 at 11:11 PM

0 · Reply

cheeseandsmile Apr. 1 at 1:39 PM

$MBRX Eli is in talks with Moleculin about license deal

1 · Reply

mokaz1 Mar. 31 at 2:34 PM

$MBRX lol

0 · Reply

Brokechump Mar. 31 at 2:23 PM

$MBRX When 5 lol

0 · Reply

mokaz1 Mar. 31 at 5:38 AM

$MBRX

0 · Reply

IVALTE Mar. 30 at 2:28 PM

$MBRX when $22?...

1 · Reply

CoffeeIV Mar. 30 at 12:49 PM

$MBRX at 2.30 ??? are we missing something ??

1 · Reply

mokaz1 Mar. 30 at 3:23 AM

$MBRX

0 · Reply

cnstogodwn Mar. 28 at 5:20 PM

$MBRX Moleculin Biotech files to sell 6.37M shares of common stock for holders. Key Takeaways: Liquidity for Insiders/Warrant Holders: This specific 6.37M share count matches a February 2026 Warrant Inducement Offer. Investors who recently exercised warrants to provide the company with cash (roughly $8.3M in gross proceeds) are now being given the legal ability to sell the resulting shares to the public. Non-Dilutive (Mostly): This is a secondary offering. Because these shares already exist (or were previously committed through warrants), the company is not necessarily creating "new" shares that would further dilute your ownership percentage. No New Capital for Company: The proceeds from the sale go to the selling holders, not to the company's treasury. Liquidity Management: The company facilitates the sale to prevent a chaotic "dumping" of shares on the market, choosing instead to handle the sale in a structured manner.

1 · Reply

cnstogodwn Mar. 28 at 4:57 PM

$MBRX Citadel Advisors holds 33K shares representing 0.62% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%. Jane Street Group holds 23K shares representing 0.42% ownership of the company. Geode Capital Management holds 15K shares representing 0.28% ownership of the company. UBS Group holds 6K shares representing 0.11% ownership of the company. Tower Research Capital LLC holds 1K shares representing 0.03% ownership of the company.

0 · Reply

mokaz1 Mar. 28 at 2:44 PM

$MBRX

0 · Reply

mokaz1 Mar. 28 at 6:58 AM

$MBRX

0 · Reply

mokaz1 Mar. 27 at 9:33 PM

$MBRX Might as well just delist.

0 · Reply

mokaz1 Mar. 27 at 9:13 PM

$MBRX An analyst actually bought this garbage stock? https://fintel.io/news/moleculin-biotech-mbrx-price-target-decreased-by-1370-to-2142-537?utm_medium=email&utm_source=fintel&utm_campaign=moleculin-biotech-mbrx-price-target-decreased-by-1370-to-2142-537&__cf_chl_tk=mKzeVZboh9YB7w5m31rrcRztBHMnN_vAXwWm9KHOJOI-1774645750-1.0.1.1-FV38TQOlXXqCppErN1o9LJ0WKqltTQbQYM8HisdngII

0 · Reply

Market Cap	13.98M
Revenue (ttm)	0.00
Net Income (ttm)	-33.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	155,323
Avg Vol	166,422
Day's Range	N/A - N/A
Shares Out	5.34M
Stochastic %K	92%
Beta	1.67
Analysts	Strong Sell
Price Target	$21.00